Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
NEW YORK, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m.
How this was made
The 30-second read
Why it matters
Positive interim data could validate the company's clinical approach, potentially boosting stock value.
Market read
The upcoming data review is a significant event for investors and could influence stock performance.
What to watch
Market-wide biotech sector downturns or macroeconomic factors could overshadow company-specific news.
Background
Protara Therapeutics is developing therapies for cancer and rare diseases, with recent focus on pediatric lymphatic malformations.
Ticker impact
High relevance due to recent news and sentiment
Potential short-term increase in stock price upon positive data release; risk of decline if data is disappointing.
The news pertains to upcoming data release, which can influence investor sentiment, but actual results are unknown.
Market effects
Potential positive impact on biotech and life sciences sector
Limited regional impact, primarily US-focused
Moderate, as biotech sector is globally interconnected
Counterpoint
The upcoming data may be disappointing, leading to a decline in stock price; avoid overreacting.
Key entities
- CompanyProtara Therapeutics
A clinical-stage biotech company specializing in cancer and rare diseases.
- Drug CandidateTARA-002
Therapeutic candidate under Phase 2 trial for pediatric lymphatic malformations.





